Factor Therapeutics is engaged in the development and commercialization of its proprietary intellectual property in wound care. Co.'s lead program, VF-0013 is a biologic product for wound care that harnesses a targeted growth factor approach to accelerate the healing process. This is a platform technology with multiple clinical applications and is being developed to treat chronic wounds that can persist for months or even years. Co. has undertaken a U.S.-centric development program, and is on the cusp of initiating a Phase II trial of its lead program in the U.S., subject to FDA approval. This Phase II program is designed to deliver the initial treatment indication of venous leg ulcers.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.